BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24710564)

  • 21. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
    Christopeit M; Labopin M; Gorin NC; Saraceni F; Passweg J; Forcade E; Maertens J; Van Lint MT; Bosi A; Niederwieser D; Ehninger G; Polge E; Mohty M; Nagler A
    Am J Hematol; 2018 Dec; 93(12):1532-1542. PubMed ID: 30218444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
    Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
    Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Poiré X; Labopin M; Cornelissen JJ; Volin L; Richard Espiga C; Veelken JH; Milpied N; Cahn JY; Yacoub-Agha I; van Imhoff GW; Michallet M; Michaux L; Nagler A; Mohty M
    Am J Hematol; 2015 Aug; 90(8):719-24. PubMed ID: 26010466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery.
    Testa U; Martucci R; Rutella S; Scambia G; Sica S; Benedetti Panici P; Pierelli L; Menichella G; Leone G; Mancuso S
    Blood; 1994 Nov; 84(10):3532-9. PubMed ID: 7949108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
    Damiani D; Tiribelli M; Geromin A; Michelutti A; Cavallin M; Sperotto A; Fanin R
    Am J Hematol; 2015 Sep; 90(9):784-9. PubMed ID: 26059733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
    Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27701. PubMed ID: 30848067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.
    Hengeveld M; Suciu S; Chelgoum Y; Marie JP; Muus P; Lefrère F; Mandelli F; Pane F; Amadori S; Fioritoni G; Labar B; Baron F; Cermak J; Bourhis JH; Storti G; Fazi P; Hagemeijer A; Vignetti M; Willemze R; de Witte T
    Bone Marrow Transplant; 2015 Mar; 50(3):341-7. PubMed ID: 25402418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
    Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
    Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.
    Baron F; Labopin M; Ruggeri A; Ehninger G; Bonifazi F; Stelljes M; Sanz J; Stuhler G; Bosi A; Kröger N; Van Lint MT; Ganser A; Forcade E; Mohty M; Gluckman E; Nagler A
    Blood Cancer J; 2019 Apr; 9(4):46. PubMed ID: 30979868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission.
    Damiani D; Tiribelli M; Geromin A; Cerno M; Zanini F; Michelutti A; Fanin R
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1621-1626. PubMed ID: 27178373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Byrne M; Volin L; Finke J; Niederwieser D; Ehninger G; Blaise D; Beelen D; Tabrizi R; Sengeloev H; Ganser A; Cornelissen JJ; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2251-2260. PubMed ID: 31271887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Mohty M; Mufti GJ; Niederwieser D; Cornelissen JJ; Janssen JJ; Milpied N; Vindelov L; Petersen E; Arnold R; Bacigalupo A; Blaise D; Craddock C; Nagler A; Frassoni F; Sadus-Wojciechowska M; Rocha V
    Bone Marrow Transplant; 2013 Feb; 48(2):238-42. PubMed ID: 22773125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
    Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Blaise D; Lopez-Corral L; Vigouroux S; Craddock C; Attal M; Jindra P; Goker H; Socié G; Chevallier P; Browne P; Sandstedt A; Duarte RF; Nagler A; Mohty M
    Bone Marrow Transplant; 2014 Mar; 49(3):389-96. PubMed ID: 24419525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study.
    Zheng FM; Zhang X; Li CF; Cheng YF; Gao L; He YL; Wang Y; Huang XJ
    Cancer Commun (Lond); 2020 Mar; 40(2-3):93-104. PubMed ID: 32175698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over.
    Santoro N; Labopin M; Ciceri F; Van Lint MT; Nasso D; Blaise D; Arcese W; Tischer J; Bruno B; Ehninger G; Koc Y; Santarone S; Huang XJ; Savani BN; Mohty M; Ruggeri A; Nagler A
    Cancer; 2019 May; 125(9):1499-1506. PubMed ID: 30620383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
    Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.